Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)

• Company Description    Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $8.08 Daily Weekly Monthly 20 Day Moving Average: 255,324 shares Shares Outstanding: 49.58 (millions) Market Capitalization: $400.57 (millions) Beta: -1.00 52 Week High: $24.30 52 Week Low: $5.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.24% 42.03% 12 Week -12.27% 2.93% Year To Date -47.12% -34.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3415 COLORADO AVE. - BOULDER,CO 80303 USA ph: 720-262-7002 fax: - ir@edgewisetx.com http://www.edgewisetx.com

• General Corporate Information    Officers Kevin Koch - President; Chief Executive Officer and Director Peter Thompson - Chairman and Director R. Michael Carruthers - Chief Financial Officer Alan Russell - Chief Scientific Officer and Director Laura A. Brege - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28036F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 49.58 Most Recent Split Date: (:1) Beta: -1.00 Market Capitalization: $400.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -114.29% vs. Previous Quarter: -15.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/22 - - 03/31/22 - -18.14 12/31/21 - -12.46 ROA 06/30/22 - - 03/31/22 - -17.53 12/31/21 - -12.13 Current Ratio 06/30/22 - - 03/31/22 - 26.85 12/31/21 - 26.97 Quick Ratio 06/30/22 - - 03/31/22 - 26.85 12/31/21 - 26.97 Operating Margin 06/30/22 - - 03/31/22 - - 12/31/21 - - Net Margin 06/30/22 - - 03/31/22 - - 12/31/21 - - Pre-Tax Margin 06/30/22 - - 03/31/22 - - 12/31/21 - - Book Value 06/30/22 - - 03/31/22 - 5.25 12/31/21 - 5.57 Inventory Turnover 06/30/22 - - 03/31/22 - - 12/31/21 - - Debt-to-Equity 06/30/22 - - 03/31/22 - 0.00 12/31/21 - 0.00 Debt-to-Capital 06/30/22 - - 03/31/22 - 0.00 12/31/21 - 0.00

Powered by Zacks Investment Research ©